Libo Zhang

Dr. Libo Zhang


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 December 2020 in Aging
Verified
Journal Article
Open access
RPRongrong Pang
Rongrong Pang
JZJun Zhao
Jun Zhao
ZGZhenhua Gan
Zhenhua Gan
ZHZhiliang Hu
Zhiliang Hu
Xiang XueXiang Xue
Xiang Xue
LZLibo Zhang
Libo Zhang
The characteristics of COVID-19 patients with autoimmune rheumatic diseases (AIRD) have rarely been reported. Patients with AIRD have suppressed immune defense function, which may increase their susceptibility to COVID-19. However, the immunosuppressive agents AIRD patients routinely used may be beneficial for protecting the cytokine storm caused by SARS-CoV-2. In this retrospective study, we included all confirmed cases in Huoshenshan Hospital from February 4 to April 9. Data were extracted from electronic medical records and were analyzed for clinical and laboratory features using SPSS (version 25.0). Of 3059 patients, 21 had the comorbidities with systematic lupus erythematosus (SLE) and/or rheumatoid arthritis (RA), including 5 with SLE, 15 with RA, and 1 with Rhupus. The proportion was 57.1% for severe cases, 61.9% for either severe or critical cases, and 4.8% for critical cases. The main manifestations, ARDS and ICU admission rate, as well as the mortality and length of hospital stay of COVID-19 in AIRD patients were similar to COVID-19 patients in the general population. Our preliminary experience shows that patients with AIRD tend to have a higher risk of SARS-CoV-2 infection, and may be at risk for a severe but less likely critical disease course. Further investigation is needed to understand the immunological features of these diseases.

23 September 2020 in Military Medical Research
Verified
Journal Article
Open access
PDF file
LZLibo Zhang
Libo Zhang
RPRong-Rong Pang
Rong-Rong Pang
QQQing-Hua Qiao
Qing-Hua Qiao
ZWZhi-Hua Wang
Zhi-Hua Wang
XXXinyi Xia
Xinyi Xia
XXXiaoli Xu
Xiaoli Xu
Background: Gastrointestinal symptoms are not rare among coronavirus disease 2019 (COVID-19) patients, but there have been no reports regarding convalescent plasma therapy for the recovery of gastrointestinal problems in COVID-19 patients. Case presentation: We present two cases of patients with COVID-19-associated recurrent diarrhea and positive fecal occult blood who successfully recovered after a one-time convalescent plasma administration. Conclusion: When COVID-19 patients develop recurrent or refractory gastrointestinal symptoms and fail to respond to the available treatment, alternative therapy with convalescent plasma administration may be considered.

9 May 2023 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MHMin Huang
Min Huang
CMChengping Ma
Chengping Ma
YLYan Li
Yan Li
RDRuiping Dong
Ruiping Dong
RPRongrong Pang
Rongrong Pang
LZLibo Zhang
Libo Zhang
The accuracy of blood group identification is the basis of blood transfusion safety. In order to increase the detection rate of weak agglutination, unexpected antibodies (UAb) and blood subtypes for pre-transfusion testing, the blood group screening process of automated blood group analyzer (ABGA) is ameliorated by introducing one static step and establishing a suspension static method (SSM). One static step was introduced in the blood group screening process of ABGA and three static time conditions were designed: 300 s, 400 s and 500 s, from which the optimal static time was selected and SSM was established; By comparing the detection of weak agglutination and UAb before and after the application of SSM, the feasibility and effect of suspension static method were verified and evaluated. The last two steps of the automatic blood group screening process were replaced with static, light centrifugation and imaging. The optimal static time parameter was selected as 400 s and SSM was established; After the application of SSM, it was verified that: (1) The detection level of weak antibodies (anti-A and anti-B) and weak antigens (weak D phenotype) could be improved by SSM, including antibodies in plasma of known type O samples with 0, 2, 4, 8, 16 and 32 times serial dilutions(simulating weak anti-A and weak anti-B), weak antibodies (anti-B) in plasma of one normal A-type sample and weak antigens on red blood cells (RBC) of 5 weak D phenotype samples (weak D antigen); (2) Three blood donor samples (type A, O and B) with known UAb were detected by SSM. The results showed that SSM could detect both weak antibodies (anti-A and anti-B) and UAb; (3) SSM was applied to detect the samples of 3 A2B and 3 subtype B blood donors and the blood subtypes could be clearly detected; (4) The number of screening samples was 95,314 and 106,814 before SSM (2018) and after (2020) the application of SSM and the positive rate of UAb (63/95,314 and 187/106,814) increased after SSM, discrepancy of which was statistically significant (χ2 = 48.42, P < 0.01). The above results demonstrate that SSM of ABGA is conducive to the detection of weak agglutination, UAb and blood subtypes in blood samples, which can improve the sensitivity of blood group detection and ensure the safety of clinical blood transfusion to a certain extent.

6 December 2023 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MHMin Huang
Min Huang
LJLu Jia
Lu Jia
SYSheng Ye
Sheng Ye
RPRongrong Pang
Rongrong Pang
CMChengping Ma
Chengping Ma
LZLibo Zhang
Libo Zhang
Since the advent of COVID-19 vaccine, the long-term monitoring and evaluation of vaccine effectiveness worldwide has never stopped. Real-world research of the mainstream vaccines in China (BBIBP-CorV and CoronaVac) is extremely valuable as a supplement to clinical research data. Venous blood of this study was collected from 111 blood donors and from 6 volunteers, who had received 2 doses of SAR-CoV-2 vaccine. Cross-sectional study and cohort study was adopted. Venous blood of 11 COVID-19 convalescent plasma donors was collected as a positive control. The seroconversion rate of neutralizing antibodies in 111 vaccine recipients was 90.99% (101/111); The level of SAR-CoV-2 antibodies peaked around 28 days after inoculation, then fast descended followed by gentle descended until it was still detectable around 280 days later. The changes in antibody levels were similar to those of the 6 participants and those of convalescent plasma donors after infection. 5 of the 6 participants still maintained a high level of neutralizing antibodies (> 60% of the peak value) around 28 days after receiving 2 doses of vaccine; one participant had an antibody reaction that was almost always negative for 4 weeks. BBIBP-CorV and CoronaVac can produce good immune effects in most vaccinators aged 20 to 59 years in Nanjing area. Nevertheless, significant individual discrepancies of the humoral immunity are still existed.

9 November 2024 in Heliyon
Verified
Journal Article
Open access
WHWenping Han
Wenping Han
JBJingjing Bao
Jingjing Bao
PHPolu Hu
Polu Hu
YLYang Liu
Yang Liu
RPRongrong Pang
Rongrong Pang
CMChengping Ma
Chengping Ma
This study introduces a completely Random Quality Control (R-QC) method for Enzyme-Linked Immunosorbent Assay (ELISA) tests and compares it with traditional Fixed Quality Control (F-QC) methods across different testing items. A random quality control system was constructed using a Time-series model, enabling fully random positioning of quality control in ELISA tests. The Coefficient of Variation (CV) for R-QC were found to be lower as compared to F-QC in Hepatitis B surface antigen (HBsAg), anti-Human Immunodeficiency Virus (anti-HIV), and Treponema Pallidum (TP) items, and there were significant differences among them. Moreover, the alarm rates and out of control rates in the R-QC groups were notably lower than those in the F-QC groups. The experimentally designed R-QC method demonstrates superior stability, reducing alarm and out of control rates, with has significant implications for improving ELISA testing at the Nanjing Blood Center.

5 May 2025 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
YYYing Yan
Ying Yan
SHShana Halemubieke
Shana Halemubieke
BSBaifeng Shan
Baifeng Shan
LZLei Zhao
Lei Zhao
YDYoubin Duan
Youbin Duan
LWLunan Wang
Lunan Wang
Assessing immune responses across diverse populations is essential for refining public health strategies. Blood donors offer valuable insights into community-level immunity. This study aims to investigate immune responses associated with inactivated COVID-19 booster immunization and breakthrough infections in blood donors. This study was conducted in a cohort of blood donors from six centers across five of China's seven major geographical regions, spanning from December 2021 to February 2023. Blood samples were collected before booster vaccination, at 1, 3, and 6 months post-vaccination, as well as 1 month post-infection. SARS-CoV-2-specific antibodies, T cell specific IFNγ levels, and neutralizing antibodies against wild-type and Omicron strains were measured. Platelet count, anti-PF4 antibody, and D-dimer levels were assessed. Demographic characteristics were analyzed to determine their impact on immunogenicity. SARS-CoV-2-specific antibodies and IFNγ levels significantly increased post-booster, peaking one month after immunization. Antibodies continued to decrease at six months, while IFNγ levels remained stable at this point. Pseudovirus neutralization assays revealed elevated neutralizing antibodies following the booster dose, with minimal response to the XBB.1.5 variant. Following Omicron infection, antibody and IFNγ levels surpassed that observed post-booster. Participants aged 36-49 and those over 50 exhibited weaker immune responses post-booster than those ages 18-35, while those with BMI above 28 showed lower IFNγ levels. This study demonstrates the utility of blood donor samples for tracking immunization effectiveness against emerging pathogens, and highlights enhanced immune responses after booster immunization and breakthrough infections, underscoring the need for tailored vaccination strategies for different groups.